Navigation Links
Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
Date:6/1/2009

Ib study (previously disclosed as Study 204), 278 treatment naive, genotype 1 patients were randomized with the following patient demographics: mean age 48.8 yrs, 61.1% male, 30% African-American or Latino, 80.7% viral load >=400,000 IU/mL and 82.1 kg mean weight.

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, including, but not limited to, statements regarding the potential for taribavirin in the treatment of hepatitis C, the continuing role of ribavirin or taribavirin in the treatment of hepatitis C and our ability to successfully pursue partnering opportunities for taribavirin, that are based on management's current expectations and involve risks and uncertainties, including, but not limited to, risks and uncertainties relating to the clinical development of new products, regulatory approval processes, that results from week 72 in the phase IIb clinical trial are not necessarily predictive of results in a phase III trial, our ability to successfully pursue partnering opportunities for taribavirin, and other risks as set forth under the caption Risk Factors in the company's most recent annual or quarterly report filed with the SEC, which factors are incorporated herein by reference. The company cautions the reader that these factors, as well as other factors described in its SEC filings, are among the factors that could cause actual results to differ materially from the expectations described in th
'/>"/>

SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. DFB Sells Coria Labs to Valeant Pharmaceuticals
2. Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million
3. Valeant Pharmaceuticals Completes Acquisition of Dow Pharmaceutical Sciences, Inc.
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... NY (PRWEB) May 23, 2013 ... GRAPHALLOY® self-lubricating bushings mounted in stainless steel ... self-lubricating properties of GRAPHALLOY with the application and ... Stainless Steel Pillow Blocks work exceptionally well ... corrosive or hostile liquids such as acids, alkalies, ...
(Date:5/23/2013)... The maker community is a contemporary group ... focus on learning practical skills while applying them creatively ... their ideas to life via crowdfunding. A subgroup within ... projects using biology. Glowing Plant has worked for months ... glow with bioluminescence genes, and has now pursued crowdfunding ...
(Date:5/23/2013)... PARK, Calif. , May 23, 2013 ... oral treatment for pain has reached an important milestone, ... trial of VBY-036 - a selective cathepsin S inhibitor. ... VBY-036 is a double-blind, randomized, placebo-controlled study designed to ... doses of VBY-036 in healthy adults. "The ...
(Date:5/23/2013)... , May 23, 2013 Northwest Biotherapeutics (NASDAQ: ... developing DCVax ® personalized immune therapies for solid ... exhibit at this year,s American Society Of Clinical Oncology ... highlight its leadership role in immune therapy.  ... annual meeting is the pre-eminent conference focused on clinical ...
Breaking Biology Technology:Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 2Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 3Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3
... NEW YORK, April 3 /PRNewswire-Asia-FirstCall/ -- China Agri-Business, ... agricultural,application products through its operating company in China, ... 31,2008. , Revenue for ... a,decrease of 3.8% as compared to $3,037,414 for ...
... CAMBRIDGE, Mass., April 3 Verenium Corporation (Nasdaq: ... development of high-performance specialty enzymes and next-generation cellulosic ... of Verenium,s demonstration-scale facility in Jennings, Louisiana, and ... with BP, Verenium is now consolidating its research ...
... tiny wires with a diameter as small as ... for devices of the future, both in technology like ... circuits for next generation of electronics. But in order ... must be precisely controlled, and researchers must better understand ...
Cached Biology Technology:China Agri-Business Announces 2008 Operating Results 2China Agri-Business Announces 2008 Operating Results 3China Agri-Business Announces 2008 Operating Results 4China Agri-Business Announces 2008 Operating Results 5Verenium Announces Organizational Changes 2Verenium Announces Organizational Changes 3Researchers peer into nanowires to measure dopant properties 2
(Date:5/23/2013)... HOUSTON (May 23, 2013) A new report ... responsible for helping pupils engage in at least 60 ... school day. , No more than half of American ... hour of vigorous or moderate intensity physical activity daily, ... , "Because children are in school for nearly half ...
(Date:5/23/2013)... Frontiers, one of the world,s largest and fastest ... new journal, Frontiers in Bioengineering and Biotechnology ... all specialties, Frontiers in Bioengineering and Biotechnology ... diverse and emerging bioengineering and biotechnology research to ... in Bioengineering and Biotechnology will provide an ...
(Date:5/22/2013)... Forest Service scientists are part of "Landscapes of Resilience", ... Foundation, will examine how collaborative planning and stewardship of ... , The TKF Foundation announced today that Landscapes of ... funding. In addition to research on the role of ... the 3-year, $585,000 grant will contribute to the creation ...
Breaking Biology News(10 mins):Schools should provide students with daily physical activity, IOM recommends 2Frontiers launches new open-access journal in Bioengineering and Biotechnology 2'Landscapes of Resilience' to study how people use nature as a source of recovery 2
... thousand species (give or take 1.3 million). That is ... the most precise calculation ever offered -- with 6.5 million ... of the total) dwelling in the ocean depths. Announced ... based on an innovative, validated analytical technique that dramatically narrows ...
... physics-based theory could give researchers a deeper understanding of ... polymers. This advance provides a better picture of how ... plastics and other polymeric materials. Kenneth S. Schweizer, ... science and engineering at the University of Illinois, and ...
... An extreme form of pregnancy-related nausea and vomiting known ... of women each year and can lead to hospitalization and ... the only victims. A joint study by ... children whose mothers suffered from HG while carrying them were ...
Cached Biology News:How many species on Earth? 8.7 million 2How many species on Earth? 8.7 million 3How many species on Earth? 8.7 million 4How many species on Earth? 8.7 million 5New theory may shed light on dynamics of large-polymer liquids 2Extreme morning sickness could lead to lifelong emotional, behavioral disorders in kids 2
... The Helios gene gun low-pressure system, 220-240 ... biomaterials into cells. This handheld device employs an ... other biomaterial-coated gold microcarriers from the inner wall ... cells. This system can be used for in ...
... Hybridization Wash Pack provides optimized blocking ... Preparation Quality Clarifier: Ready-to-use wash solutions ... SigmaScreen(tm) APS Coated Slides for Microarrays ... Hybridization Blocking Buffer: 1L • Microarray ...
Mouse polyclonal antibody raised against a partial recombinant MHC2TA. NCBI Entrez Gene ID = 4261...
Mouse monoclonal antibody raised against a partial recombinant JRKL. NCBI Entrez Gene ID = JRKL...
Biology Products: